ANL

Adlai Nortye GroupD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$16.00

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$11.00

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$6.50

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Sentiment is cautious-neutral. Primary-source confirmation improved the setup versus the raw packet: the company absorbed a major negative in the May 30, 2025 BURAN failure and discontinuation [#PR-2025-05-30], then recapitalized with a $140.0 million PIPE on February 3, 2026 [#PR-2026-02-03] and advanced AN9025 into Phase 1 with first-patient dosing on February 12, 2026 [#PR-2026-02-12]. That said, forward visibility is still weak because the remaining thesis depends on very early-stage assets, and some previously guided milestones from older disclosures are not yet clearly resolved in the sources checked. This remains more of a funded monitoring story than a high-conviction bullish setup.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystPost-BURAN balance-sheet reset is largely in placeHigh impact

After discontinuing buparlisib following the failed Phase 3 BURAN readout [#PR-2025-05-30], Adlai raised approximately $140.0 million in a February 3, 2026 private placement, materially reducing immediate financing stress and allowing focus on RAS and immunotherapy assets [#PR-2026-02-03]. Near-term upside from this reset looks partly absorbed, but it lowers binary insolvency risk.

2026-07-15catalystAN4035 IND timing is a secondary pipeline optionHigh impact

The December 29, 2025 6-K said Adlai expects to submit an IND for AN4035 in the middle of 2026 [#6K-2025-12-29]. Hitting that timing would support the view that the post-BURAN company still has more than one forward program, though the value impact should stay below AN9025 until human data arrive.

2026-09-30eventAN9025 clinical execution becomes the lead proof pointHigh impact

Adlai announced first-patient dosing in the U.S. Phase 1 AN9025 study on February 12, 2026 [#PR-2026-02-12]. With AN2025 discontinued, incremental enrollment, safety, or early pharmacology updates on AN9025 are now the main stock-specific upside driver.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology